J Pathol Transl Med.  2024 Nov;58(6):291-298. 10.4132/jptm.2024.10.22.

Next step of molecular pathology: next-generation sequencing in cytology

• Silva RSd
• Schmitt F

• KMID: 2560670
• DOI: http://doi.org/10.4132/jptm.2024.10.22

Abstract

The evolving landscape of precision oncology underscores the pivotal shift from morphological diagnosis to treatment decisions driven by molecular profiling. Recent guidelines from the European Society for Medical Oncology recomend the use of next-generation sequencing (NGS) across a broader range of cancers, reflecting its superior efficiency and clinical value. NGS not only updates oncology testing by offering quicker, sample-friendly, and sensitive analysis but also reduces the need for multiple individual tests. Cytology samples, often obtained through less invasive methods, can yield high-quality genetic material suitable for molecular analysis. This article focuses on optimizing the use of cytology samples in NGS, and outlines their potential benefits in identifying actionable molecular alterations for targeted therapies across various solid tumors. It also addresses the need for validation studies and the strategies to incorporate or combine different types of samples into routine clinical practice. Integrating cytological and liquid biopsies into routine clinical practice, alongside conventional tissue biopsies, offers a comprehensive approach to tumor genotyping, early disease detection, and monitoring of therapeutic responses across various solid tumor types. For comprehensive biomarker characterization, all patient specimens, although limited, is always valuable.

Keyword

Cytology; Molecular pathology; Next generation sequencing; Body fluid

Figure

• 

  Fig. 1. Schematic illustration of the workflow and applicability of the NGS assay on cytological samples. CC, cancer cells; LBC, liquid based cytology; MSI-H, microsatellite instability–high; NGS, next generation sequencing; TMB-H, high tumor mutation burden.

Reference

References

1. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31:1491–505.

2. Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2021; 35:588–606.

3. Stenzinger A, Cuffel B, Paracha N, et al. Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator. Oncologist. 2023; 28:e242–53.

4. Danesi R, Fogli S, Indraccolo S, et al. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. ESMO Open. 2021; 6:100040.

5. Pisapia P, Pepe F, Sgariglia R, et al. Next generation sequencing in cytology. Cytopathology. 2021; 32:588–95.

6. Turner SA, Abou Shaar R, Yang Z. The basics of commonly used molecular techniques for diagnosis, and application of molecular testing in cytology. Diagn Cytopathol. 2023; 51:83–94.

7. Roy-Chowdhuri S, Dacic S, Ghofrani M, et al. Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies: guideline from the College of American Pathologists in collaboration with the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Arch Pathol Lab Med. 2020; 144:933–58.

8. Morii E, Hatanaka Y, Motoi N, et al. Guidelines for handling of cytological specimens in cancer genomic medicine. Pathobiology. 2023; 90:289–311.

9. Sura GH, Tran K, Fu C, et al. Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing. J Am Soc Cytopathol. 2023; 12:10–9.

10. Hwang DH, Garcia EP, Ducar MD, Cibas ES, Sholl LM. Next-generation sequencing of cytologic preparations: an analysis of quality metrics. Cancer Cytopathol. 2017; 125:786–94.

11. Kim H, Chung JH. Biomarker testing of cytology specimens in personalized medicine for lung cancer patients. J Pathol Transl Med. 2022; 56:326–33.

12. Roy-Chowdhuri S, Stewart J. Preanalytic variables in cytology: lessons learned from next-generation sequencing: the MD Anderson experience. Arch Pathol Lab Med. 2016; 140:1191–9.

13. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017; 19:4–23.

14. Souza da Silva R, Pinto R, Cirnes L, Schmitt F. Tissue management in precision medicine: what the pathologist needs to know in the molecular era. Front Mol Biosci. 2022; 9:983102.

15. Roy-Chowdhuri S, Goswami RS, Chen H, et al. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015; 123:659–68.

16. Zannini G, Tedesco I, Cozzolino I, et al. A critical issue in lung cancer cytology and small biopsies: DNA and RNA extraction from archival stained slides for biomarker detection through real time PCR and NGS: the experience in pathological anatomy unit. Diagnostics (Basel). 2023; 13:1637.

17. Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, et al. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: a worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathol. 2017; 125:615–26.

18. Hofman P. What is new in biomarker testing at diagnosis of advanced non-squamous non-small cell lung carcinoma? Implications for cytology and liquid biopsy. J Mol Pathol. 2021; 2:147–72.

19. Hofman P, Berezowska S, Kazdal D, et al. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers. Virchows Arch. 2024; 484:233–46.

20. de Jager VD, Timens W, Bayle A, et al. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. Lancet Reg Health Eur. 2024; 38:100839.

21. Roh MH. The utilization of cytologic and small biopsy samples for ancillary molecular testing. Mod Pathol. 2019; 32:77–85.

22. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021; 19:439–57.

23. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021; 19:439–57.

24. Roy-Chowdhuri S, Chen H, Singh RR, et al. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017; 30:499–508.

25. Singhi AD, McGrath K, Brand RE, et al. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut. 2018; 67:2131–41.

26. Paniccia A, Polanco PM, Boone BA, et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology. 2023; 164:117–33.

27. Souza da Silva R, Pina MJ, Cirnes L, Gouveia L, Albergaria A, Schmitt F. Comprehensive genomic studies on the cell blocks of pancreatic cancer. Diagnostics (Basel). 2024; 14:906.

28. Redegalli M, Schiavo Lena M, Cangi MG, et al. Proposal for a new pathologic prognostic index after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma (PINC). Ann Surg Oncol. 2022; 29:3492–502.

29. Huang Y, Chan SJ, Wright JD, et al. Does the adoption of molecular testing cause decreased thyroidectomy rates in a national cohort? A quasiexperimental study of high- versus low-adoption states. Thyroid. 2024; 34:388–98.

30. McMurtry V, Canberk S, Deftereos G. Molecular testing in fine-needle aspiration of thyroid nodules. Diagn Cytopathol. 2023; 51:36–50.

31. Schmitt F, da Silva RS. False positive in thyroid FNA: causes and how to avoid them. In: Kakudo K, Liu Z, Jung CK, Hirokawa M, Bychkov A, Lai CR, eds. Thyroid FNA cytology. Singapore: Springer Nature Singapore, 2023; 233-44.

32. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018; 36:7–13.

33. Dupain C, Masliah-Planchon J, Gu C, et al. Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial. Mol Oncol. 2021; 15:104–15.

34. Gornjec A, Novakovic S, Stegel V, et al. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma. BMC Cancer. 2019; 19:296.

35. Nozaki T, Sakamoto I, Kagami K, et al. Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens. Cancer Cytopathol. 2022; 130:640–9.

36. Malapelle U, Pepe F, Pisapia P, et al. Reference standards for gene fusion molecular assays on cytological samples: an international validation study. J Clin Pathol. 2023; 76:47–52.

37. Schmitt F, Di Lorito A, Vielh P. Molecular testing on cytology for gene fusion detection. Front Med (Lausanne). 2021; 8:643113.

38. Wolff HB, Steeghs EMP, Mfumbilwa ZA, et al. Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non-small-cell lung cancer in the Netherlands. JCO Precis Oncol. 2022; 6:e2200201.

39. Jager L, Jennings LJ, Dittmann D, Blanco J, Choy B, Nayar R. Supernatant fluid from endobronchial ultrasound-guided transbronchial needle aspiration for rapid next-generation sequencing. J Am Soc Cytopathol. 2024; 13:340–5.

40. Pepe F, Pisapia P, Gristina V, et al. Tumor mutational burden on cytological samples: a pilot study. Cancer Cytopathol. 2021; 129:460–7.

41. Alborelli I, Bratic Hench I, Chijioke O, et al. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients. Lung Cancer. 2020; 149:84–9.

42. Amemiya K, Hirotsu Y, Mochizuki H, et al. Deep targeted sequencing of cytological tumor cells using whole genome amplification. Cancer Cytopathol. 2023; 131:58–68.

43. Gosney JR, Paz-Ares L, Janne P, et al. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. ESMO Open. 2023; 8:101587.

44. Pisapia P, Pepe F, Iaccarino A, et al. Next generation sequencing in cytopathology: focus on non-small cell lung cancer. Front Med (Lausanne). 2021; 8:633923.

45. Marmarelis ME, Scholes DG, McGrath CM, et al. Brief report: impact of reflex testing on tissue-based molecular genotyping in patients with advanced non-squamous non-small cell lung cancer. Clin Lung Cancer. 2024; 25:262–5.

46. Souza da Silva R, Schmitt F. Minimally invasive, maximally effective: the power of precision cytoanalysis on effusion samples: a comprehensive exploration from traditional methods to innovative approaches. Surg Pathol Clin. 2024; 17:453–81.

47. Durin L, Pradines A, Basset C, et al. Liquid biopsy of non-plasma body fluids in non-small cell lung cancer: look closer to the tumor! Cells. 2020; 9:2486.